Lyell Immunopharma (LYEL) Interest & Investment Income (2020 - 2026)

Lyell Immunopharma has reported Interest & Investment Income for 7 years, with the latest figure at -$251000.0 in Q1 2026.

• Quarterly Interest & Investment Income fell 88.72% year-over-year to -$251000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$167000.0 (down 129.72% YoY) and the FY2025 annual result came in at -$49000.0, down 112.73% from the prior year.
• Interest & Investment Income retreated to -$251000.0 in Q1 2026 per LYEL's latest filing, from $41000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $3.7 million in Q1 2023 and troughed at -$5.0 million in Q1 2022.
• A 5-year average of $94941.2 and a median of $7000.0 in 2024 frame the typical range for Interest & Investment Income.
• The widest YoY moves for Interest & Investment Income: up 253.85% in 2022, down 5251.61% in 2022.
• Over 5 years, Interest & Investment Income stood at $2.4 million in 2022, then slumped by 54.65% to $1.1 million in 2023, then sank by 143.15% to -$469000.0 in 2024, then soared by 108.74% to $41000.0 in 2025, then sank by 712.2% to -$251000.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered -$251000.0, $41000.0, and $144000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.